Journal of Shanghai Jiao Tong University (Medical Science) >

2022 , Vol. 42 >Issue 10: 1383 - 1393

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.10.003

Basic research

Function of UCHL3 in maintaining the survival of FLT3-ITD positive acute myeloid leukemia cells

  • Jiacheng HU ,
  • Qian ZHU ,
  • Jiaqi WANG ,
  • Yingli WU ,
  • Hu LEI
Expand
  • Department of Pathophysiology, Shanghai Jiao Tong University College of Basic Medical Sciences, Shanghai 200025, China
WU Yingli, E-mail: wuyingli@shsmu.edu.cn.
LEI Hu, E-mail: hulei@shsmu.edu.cn

Received date: 2022-04-04

  Accepted date: 2022-09-16

  Online published: 2022-12-02

Supported by

National Natural Science Foundation of China(82170145);Innovative Research Team of High-Level Local Universities in Shanghai(SHSMU-ZDCX20211802)

Fold

Abstract

Objective ·To explore differently expressed deubiquitinases in acute myeloid leukemia (AML) cells with internal tandem duplications of the FLT3 (FLT3-ITD) gene mutation. Methods ·The expressions of some deubiquitinases were detected by Western blotting after transforming exogenous FLT3-ITD or the use of FLT3-ITD inhibitor. The Cancer Genome Atlas (TCGA) public database was used to analyze the expression of UCHL3 in FLT3-ITD-positive patients and its correlation with the prognosis of AML patients. Certain deubiquitinase was knocked down by short hairpin RNA (shRNA) in AML cell lines. Cell counting, CCK-8 assay, flow cytometry and wright stain were used to detect the effect of certain deubiquitinase on the function of AML cells and the combined effect of knockdown of corresponding deubiquitinase or using its inhibitor with all-trans-retinoic acid (ATRA). Results ·Expression of FLT3-ITD in Ba/F3 cells significantly induced the protein expression of UCHL3, while inhibition of FLT3-ITD activity in MOLM-13 and MV4-11 cell lines significantly inhibited the expression of UCHL3 in a time- and concentration-dependent manner. TCGA database analysis showed that there was a significant positive correlation between the expression of FLT3 and the expression of UCHL3 in AML (P=0.000), and a significant negative correlation between the expression of UCHL3 and the survival rate of AML patients (P=0.016). UCHL3 knockdown inhibited proliferation and promoted apoptosis of MOLM-13 and MV4-11 cells, and the expression of differentiation-related transcription factors PU.1 and C/EBPβ were significantly increased. Knockdown of UCHL3 significantly enhanced the apoptosis of MOLM-13 and MV4-11 cells induced by 100 nmol/L ATRA, and the apoptosis-related caspase proteins PARP1, caspase 9 and caspase 3 were significantly cleaved. Meanwhile, UCHL3 knockdown cells showed more features of small nuclear volume, nuclear depression, and rod-shaped or irregular cells after ATRA treatment. The dose-response curves of ATRA and TCID detected by CCK-8 assay showed that UCHL3 inhibitor TCID and ATRA synergistic inhibited FLT3-ITD-positive AML cells survival. Conclusion ·FLT3-ITD up-regulates UCHL3 expression and promotes the survival of AML cells. UCHL3 is negatively correlated with the prognosis of AML patients. Knockdown or inhibition of UCHL3 combines with ATRA to inhibit the survival of FLT3-ITD-positive AML cells.

Key words： ubiquitin carboxyl-terminal hydrolase L3 (UCHL3); acute myeloid leukemia (AML); FMS-like tyrosine kinase 3 (FLT3); FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD); all-trans retinoic acid (ATRA)

Cite this article

Jiacheng HU , Qian ZHU , Jiaqi WANG , Yingli WU , Hu LEI . Function of UCHL3 in maintaining the survival of FLT3-ITD positive acute myeloid leukemia cells[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(10) : 1383 -1393 . DOI: 10.3969/j.issn.1674-8115.2022.10.003

References

1 DE KOUCHKOVSKY I, ABDUL-HAY M. Acute myeloid leukemia: a comprehensive review and 2016 update[J]. Blood Cancer J, 2016, 6(7): e441.
2 SHORT N J, RYTTING M E, CORTES J E. Acute myeloid leukaemia[J]. Lancet, 2018, 392(10147): 593-606.
3 ANTAR A I, OTROCK Z K, JABBOUR E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions[J]. Leukemia, 2020, 34(3): 682-696.
4 WU M, LI C T, ZHU X P. FLT3 inhibitors in acute myeloid leukemia[J]. J Hematol Oncol, 2018, 11(1): 133.
5 MOREAU P, RICHARDSON P G, CAVO M, et al. Proteasome inhibitors in multiple myeloma: 10 years later[J]. Blood, 2012, 120(5): 947-959.
6 MANASANCH E E, ORLOWSKI R Z. Proteasome inhibitors in cancer therapy[J]. Nat Rev Clin Oncol, 2017, 14(7): 417-433.
7 REINCKE M, SBIERA S, HAYAKAWA A, et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease[J]. Nat Genet, 2015, 47(1): 31-38.
8 WILLIAMS S A, MAECKER H L, FRENCH D M, et al. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma[J]. Cell, 2011, 146(6): 918-930.
9 MENNERICH D, KUBAICHUK K, KIETZMANN T. DUBs, hypoxia, and cancer[J]. Trends Cancer, 2019, 5(10): 632-653.
10 HE M J, ZHOU Z, WU G, et al. Emerging role of DUBs in tumor metastasis and apoptosis: therapeutic implication[J]. Pharmacol Ther, 2017, 177: 96-107.
11 AKIYAMA H, UMEZAWA Y, ISHIDA S, et al. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress[J]. Cancer Lett, 2019, 453: 84-94.
12 WEISBERG E L, SCHAUER N J, YANG J, et al. Inhibition of USP10 induces degradation of oncogenic FLT3[J]. Nat Chem Biol, 2017, 13(12): 1207-1215.
13 SCHAUER N J, MAGIN R S, LIU X X, et al. Advances in discovering deubiquitinating enzyme (DUB) inhibitors[J]. J Med Chem, 2020, 63(6): 2731-2750.
14 OUYANG L L, YAN B, LIU Y T, et al. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor[J]. Signal Transduct Target Ther, 2020, 5(1): 78.
15 SONG Z W, LI J H, ZHANG L, et al. UCHL3 promotes pancreatic cancer progression and chemo-resistance through FOXM1 stabilization[J]. Am J Cancer Res, 2019, 9(9): 1970-1981.
16 LI J N, ZHENG Y, LI X F, et al. UCHL3 promotes proliferation of colorectal cancer cells by regulating SOX12 via AKT/mTOR signaling pathway[J]. Am J Transl Res, 2020, 12(10): 6445-6454.
17 SATO A, KAMIO N, YOKOTA A, et al. C/EBPβ isoforms sequentially regulate regenerating mouse hematopoietic stem/progenitor cells[J]. Blood Adv, 2020, 4(14): 3343-3356.
18 SCOTT E W, SIMON M C, ANASTASI J, et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages[J]. Science, 1994, 265(5178): 1573-1577.
19 MUELLER B U, PABST T, FOS J, et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression[J]. Blood, 2006, 107(8): 3330-3338.
20 KHAN I, HALASI M, PATEL A, et al. FOXM1 contributes to treatment failure in acute myeloid leukemia[J]. JCI Insight, 2018, 3(15): e121583.
21 LIU LL, ZHANG D H, MAO X, et al. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia[J]. Biochem Biophys Res Commun, 2014, 446(1): 280-285.
22 SHENG Y, YU C J, LIU Y, et al. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML[J]. Nat Commun, 2020, 11(1): 928.
23 KHAN I, HALASI M, ZIA M F, et al. Nuclear FOXM1 drives chemoresistance in AML[J]. Leukemia, 2017, 31(1): 251-255.
24 SONG Z W, TU X Y, ZHOU Q, et al. A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair[J]. Cell Death Dis, 2019, 10(6): 398.
25 WANG Z Y, CHEN Z. Acute promyelocytic leukemia: from highly fatal to highly curable[J]. Blood, 2008, 111(5): 2505-2515.
26 SCHOLL S, MüLLER R, CLEMENT J H, et al. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells[J]. Leuk Res, 2006, 30(5): 633-642.
27 CHI H T, LY B T K, VU H A, et al. Synergistic effect of all?trans retinoic acid in combination with protein kinase C412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells[J]. Mol Med Rep, 2015, 11(5): 3969-3975.
Options
Outlines

/

〈 〉